A driver leaves the city-owned parking lot at Neil and Washington streets Wednesday in downtown Champaign. The lot will be turned into the north end of the city’s Downtown Plaza over the next two ...

SOUTH LAKE TAHOE, Calif. – After several delays to hold the meeting discussing how the California Department of Fish and Wildlife (CDFW) manages black bears in the Tahoe Basin, regional manager Morgan ...

Pre-Functionality Protocol Tokens, over which the SEC would retain jurisdiction via investment-contract-based oversight; Functional Protocol Tokens, which operate in live systems and fit within the ...

Current political and economic issues succinctly explained. Welcome to the Daily News Brief, CFR’s flagship morning newsletter summarizing the top global news and analysis of the day. What Hamas is ...

HUNTSVILLE — Jerious Singletary and Tr’e Williams have each committed to their new schools on the first day of the early signing period. Singletary committed to North Texas, and Williams committed to ...

A Solidity engineer proposed a protocol earlier this year using zero-knowledge proofs and transaction relayers to enable a Secret Santa-like feature on Ethereum. Ethereum researchers are working on ...

Turkish, Qatari and Egyptian officials met Wednesday in Cairo to discuss the second phase of the Israel-Hamas ceasefire deal. The meeting is said to have included Turkey and Egypt's intelligence ...

In select U.S. states, residents can add their driver's license or state ID to the Apple Wallet app on the iPhone and Apple Watch, and then use it to display proof of identity or age at select ...

Introduction Epidermolysis bullosa (EB) is a group of rare genetic skin disorders characterised by skin and mucosal fragility, leading to painful blisters and erosions. Among its subtypes, the severe ...

Remote and hybrid work have become defining features of the postpandemic economy. While most employees seem to love it, the initial optimistic assessment during the pandemic that remote work was a ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a phase 2 study. The U.K.-based pharma had been evaluating the antisense ...